Rheumatic manifestations of hepatitis

Current Opinion in Rheumatology

Volumn 22, Issue 1, 2010, Pages 91-93

  Vassilopoulos, Dimitrios ^a   Manolakopoulos, Spilios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Anti TNF agents; Hepatitis B; Hepatitis C; Rheumatoid arthritis; Rituximab

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENTECAVIR; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LAMIVUDINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; RIBAVIRIN; RITUXIMAB; STEROID; TELBIVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

ARTHRITIS; CHRONIC HEPATITIS; CLINICAL TRIAL; CRYOGLOBULINEMIA; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; HEPATITIS B; HEPATITIS C; HUMAN; LOW DRUG DOSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; SPONDYLOARTHROPATHY; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; COOPERATIVE BEHAVIOR; CRYOGLOBULINEMIA; HEPATITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT CARE TEAM; RHEUMATIC DISEASES;

EID: 73649085526     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328333ba5d     Document Type: Review

References (33)

1. Vassilopoulos D, Calabrese LH. Virally associated arthritis 2008: Clinical, epidemiologic, and pathophysiologic considerations. Arthritis Res Ther 2008; 10:215.
2. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359:1486-1500.
3. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009; 49:1335-1374.
4. Deuffic-Burban S, Poynard T, Sulkowski MS, et al. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007; 14:107-115.
5. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
6. Lok ASF, McMahon BJ. AASLD Practice Guidelines. Chronic hepatitis B: update 2009. Available at www.aasld.org.
7. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, et al. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8:167-178.
8. Vassilopoulos D, Calabrese LH. Rheumatic manifestations of hepatitis C infection. Curr Rheumatol Rep 2003; 5:200-204.
9. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999; 42:2204-2212.
10. Buskila D. Hepatitis C-associated rheumatic disorders. Rheum Dis Clin North Am 2009; 35:111-123.
11. Rosner I, Rozenbaum M, Toubi E, et al. The case for hepatitis Carthritis. Semin Arthritis Rheum 2004; 33:375-387.
12. Bombardieri M, Alessandri C, Labbadia G, et al. Role of anticyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther 2004; 6:R137-R141.
13. Koga T, Migita K, Miyashita T, et al. Determination of anticyclic citrullinated peptide antibodies in the sera of patients with liver diseases. Clin Exp Rheumatol 2008; 26:121-124.
14. Vassilopoulos D, Calabrese LH. Hepatitis C virus infection and vasculitis. Implications of antiviral and immunosuppressive therapies. Arthritis Rheum 2002; 46:585-597.
15. Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritis nodosa: Clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84:313-322.
16. Arroyo V, Gines P, Rimola A, et al. Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. Am J Med 1986; 81:104-122.
17. De Ledinghen V, Heresbach D, Fourdan O, et al. Anti-inflammatory drugs and variceal bleeding: A case-control study. Gut 1999; 44:270-273.
18. Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: Incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford) 2005; 44:1016-1020.
19. Saag KG, Teng GG, Patkar NM, et al. American College ofRheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762-784.
20. Lucidarme D, Foucher J, Le Bail B, et al. Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49:1083-1089.
21. Ishii N, Watashi K, Hishiki T, et al. Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol 2006; 80:4510-4520.
22. Giannitti C, Benucci M, Caporali R, et al. Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection. Int J Immunopathol Pharmacol 2009; 22:543-546.
23. Ferri C, Ferraccioli G, Ferrari D, et al. Safety of antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008; 35:1944-1949.
24. Parke FA, Reveille JD. Antitumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004; 51:800-804.
25. Zuckerman E, Keren D, Rozenbaum M, et al. Hepatitis C virus-related arthritis: Characteristics and response to therapy with interferon alpha. Clin Exp Rheumatol 2000; 18:579-584.
26. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004; 63 (Suppl 2):ii18- ii24.
27. Vassilopoulos D, Calabrese LH. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Curr Opin Rheumatol 2007; 19:619-625.
28. Cacoub P, Delluc A, Saadoun D, et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008; 67:283-287.
29. Terrier B, Saadoun D, Sene D, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virusrelated vasculitis: A long-term followup study of thirty-two patients. Arthritis Rheum 2009; 60:2531-2540.
30. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49:S156-S165.
31. Koo YX, Tan DS, Tan IB, et al. Hepatitis B virus reactivation in a patient with resolved hepatitis B virus infection receiving maintenance rituximab for malignant B-cell lymphoma. Ann Intern Med 2009; 150:655-656.
32. YeoW, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27:605-611.
33. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: Assessment and preventive strategies. Ann Rheum Dis 2006; 65:983-989.